既往盆腔放疗后原发性直肠腺癌的治疗:超分割加速再照射的作用
本研究纳入10例因其他原发恶性肿瘤曾接受盆腔放疗、后发生原发性直肠腺癌的患者,评估超分割加速再照射(1.5 Gy 每日两次,总剂量39 Gy至45 Gy)的疗效与毒性;中位随访3.2年,10例中7例再照射后接受手术,全组3年无局部进展率为62%、手术患者为80%,3年总生存率为100%,出现1例急性3级腹泻和1例晚期3级骶骨功能不全性骨折。
要点
- 10例既往盆腔放疗后原发性直肠腺癌患者接受超分割加速再照射,1.5 Gy 每日两次至总剂量39 Gy至45 Gy。
- 中位随访3.2年,全组3年无局部进展率62%,手术患者80%,3年总生存率100%。
- 出现1例急性3级腹泻和1例晚期3级骶骨功能不全性骨折。
核心结论
- 超分割加速再照射耐受性良好,在既往接受盆腔放疗的原发性直肠癌患者中无局部进展率和总生存率结果令人期待。
- 该方法联合同期化疗和手术似乎是该患者人群可行的治疗策略。
研究设计与样本
- 本研究识别了10例因其他原发恶性肿瘤有既往盆腔放疗史、并因原发性直肠腺癌接受超分割加速再照射的患者。
- 放疗采用1.5 Gy 每日两次分割,总剂量39 Gy至45 Gy。
主要发现
- 中位随访时间为3.2年(范围0.6-9.0年)。
- 10例患者中7例在再照射后接受手术。
- 全组3年无局部进展率为62%,接受手术患者为80%。
- 3年总生存率为100%,3例死亡分别发生在再照射后4.7年、6.5年和9.0年。
- 1例患者出现急性3级腹泻毒性,1例患者出现晚期3级骶骨功能不全性骨折毒性。
临床怎么用
- 作者认为,超分割加速再照射联合同期化疗和手术似乎是该类患者人群可行的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Previous studies have reported that hyperfractionated accelerated reirradiation can be used as part of multimodality treatment of locally recurrent rectal cancer with acceptable toxicity and promising outcomes. The purpose of this study was to evaluate the outcomes and toxicity of hyperfractionated accelerated reirradiation for patients with primary rectal adenocarcinoma and a history of prior pelvic radiation for other primary malignancies. METHODS AND MATERIALS: We identified 10 patients with a prior history of pelvic radiation for other primary malignancies who were treated with hyperfractionated accelerated reirradiation for primary rectal adenocarcinoma. Radiation therapy was administered with 1.5 Gy twice daily fractions to a total dose of 39 Gy to 45Gy. RESULTS: The median follow-up time was 3.2 years (range, 0.6-9.0 years). Seven of 10 patients received surgery after reirradiation. The 3-year freedom-from-local-progression rate was 62% for all patients and 80% for patients who underwent surgery. The 3-year overall survival rate was 100%, with 3 deaths occurring at 4.7, 6.5, and 9.0 years after reirradiation. One patient had an acute Grade 3 toxicity of diarrhea, and 1 patient experienced a late Grade 3 toxicity of sacral insufficiency fracture. CONCLUSIONS: Hyperfractionated accelerated reirradiation was well tolerated with promising rates of freedom from local progression and overall survival in patients with primary rectal cancer with a history of prior pelvic radiation therapy. This approach, along with concurrent chemotherapy and surgery, appears to be a viable treatment strategy for this patient population.
引用
- Jensen G, Tao R, Eng C, et al. Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018. PMID: 30370360. doi:10.1016/j.adro.2018.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。